CVE-2026-7884

MEDIUM
Published September 14, 2026

IBM Cognos Analytics 12.1.0 through 12.1.3 FP1, and 12.0.4 through 12.0.4 FP2 allows a non-privileged user to edit their given name and surname to include malicious JavaScript code. When an administrator later accesses the user account management panel and views that user's permissions, the...

Full CISO analysis pending enrichment.

How severe is it?

CVSS 3.1
5.4 / 10
EPSS
0.2%
chance of exploitation in 30 days
Higher than 14% of all CVEs
Exploitation Status
No known exploitation
Sophistication
N/A

What is the attack surface?

AV AC PR UI S C I A
AV Network
AC Low
PR Low
UI Required
S Changed
C Low
I Low
A None

What should I do?

No patch available

Monitor for updates. Consider compensating controls or temporary mitigations.

Which compliance frameworks are affected?

Compliance analysis pending. Sign in for full compliance mapping when available.

Frequently Asked Questions

What is CVE-2026-7884?

IBM Cognos Analytics 12.1.0 through 12.1.3 FP1, and 12.0.4 through 12.0.4 FP2 allows a non-privileged user to edit their given name and surname to include malicious JavaScript code. When an administrator later accesses the user account management panel and views that user's permissions, the malicious JavaScript code is executed. This could result in the cookies from the administrator being compromised.

Is CVE-2026-7884 actively exploited?

No confirmed active exploitation of CVE-2026-7884 has been reported, but organizations should still patch proactively.

How to fix CVE-2026-7884?

No patch is currently available. Monitor vendor advisories for updates.

What is the CVSS score for CVE-2026-7884?

CVE-2026-7884 has a CVSS v3.1 base score of 5.4 (MEDIUM). The EPSS exploitation probability is 0.23%.

What are the technical details?

Original Advisory

IBM Cognos Analytics 12.1.0 through 12.1.3 FP1, and 12.0.4 through 12.0.4 FP2 allows a non-privileged user to edit their given name and surname to include malicious JavaScript code. When an administrator later accesses the user account management panel and views that user's permissions, the malicious JavaScript code is executed. This could result in the cookies from the administrator being compromised.

Weaknesses (CWE)

CWE-79 — Improper Neutralization of Input During Web Page Generation ('Cross-site Scripting'): The product does not neutralize or incorrectly neutralizes user-controllable input before it is placed in output that is used as a web page that is served to other users.

  • [Architecture and Design] Use a vetted library or framework that does not allow this weakness to occur or provides constructs that make this weakness easier to avoid [REF-1482]. Examples of libraries and frameworks that make it easier to generate properly encoded output include Microsoft's Anti-XSS library, the OWASP ESAPI Encoding module, and Apache Wicket.
  • [Implementation, Architecture and Design] Understand the context in which your data will be used and the encoding that will be expected. This is especially important when transmitting data between different components, or when generating outputs that can contain multiple encodings at the same time, such as web pages or multi-part mail messages. Study all expected communication protocols and data representations to determine the required encoding strategies. For any data that will be output to another web page, especially any data that was received from external inputs, use the appropriate encoding on all non-alphanumeric characters. Parts of the same output document may require different encodings, which will vary depending on whether the output is in the: etc. Note that HTML Entity Encoding is only appropriate for the HTML body. Consult the XSS Prevention Cheat Sheet [REF-724] for more details on the types of encoding and escaping that are needed. HTML body Element attributes (such as src="XYZ") URIs JavaScript sections Casca

Source: MITRE CWE corpus.

CVSS Vector

CVSS:3.1/AV:N/AC:L/PR:L/UI:R/S:C/C:L/I:L/A:N

Timeline

Published
September 14, 2026
Last Modified
September 16, 2026
First Seen
September 14, 2026